Published in final edited form as:

Arch Osteoporos. ; 14(1): 83. doi:10.1007/s11657-019-0629-7.

Osteoporosis in Colorectal Cancer Survivors: Analysis of the Linkage between SWOG Trial Enrollees and Medicare Claims

Afsaneh Barzi, MD, PhD¹, Dawn L. Hershman, MD, MS², Cathee Till³, William E. Barlow³, Scott Ramsey, MD, PhD⁴, Heinz-Josef Lenz, MD¹, Howard S. Hochster, MD⁵, Joseph M. Unger, PhD, MS³

¹University of Southern California, Los Angeles, CA

²Columbia University Medical Center, New York, NY

³SWOG Statistical Center, Seattle, WA

⁴Fred Hutchinson Cancer Research Center, Seattle, WA

⁵Rutgers Cancer Institute of New Jersey

Abstract

Introduction: In US, the population of colorectal cancer survivors (CRCS) is on the rise. Calcium and Vitamin D are the common thread between colorectal cancer and osteoporosis. We set to explore the patterns and prevalence of osteoporosis (OP) and osteoporotic fractures (OF) in CRCS who received fluorouracil based therapy on SWOG trials.

Methods: Data for CRCS from three SWOG phase III treatment trials between 1994–2000 (N=3775) were linked to Medicare claims (N=1233). OP was identified using ICD9 and HCPCS codes; OF was defined using a more restricted set of codes. We compared patterns of OP, OF, and screening for OP by gender in CRCS. Given the gender disparities in the rates of OP and OF, we used data from the National Health Interview Survey (NHIS) and the National Hospital Discharge Survey (NHDS) to assess the ratio of OF in females and males in general population.

Results: 47% of females and 15% of men CRCS had OP claims. Female CRCS were more likely than males to have OP (HR=4.76 [3.77–6.01], $p<0.0001$) and OF (HR=2.64 [2.04–3.42], $p<0.0001$). In the general population the female to male ratio of OF was 1.67 as opposed to 2.90 in

Corresponding Author: Afsaneh Barzi, MD, PhD, Assistant Professor of Medicine, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave. Suite 3440, Los Angeles, CA 90033, Tel: 323-865-3829; Fax: 323-865-0061, barzi@usc.edu.

Prior Presentation: Presented in part at the 53rd Annual Meeting of the American Society of Clinical Oncology, June 2–6, 2017, Chicago, IL, as poster presentation.

Afsaneh Barzi: No conflict of interest

Dawn L. Hershman: No conflict of interest

Cathee Till: No conflict of interest

William E. Barlow: No conflict of interest

Scott Ramsey: No conflict of interest

Heinz-Josef Lenz: No conflict of interest

Howard S. Hochster: No conflict of interest

Joseph M. Unger: No conflict of interest

CRCS; indicating a significantly larger gender disparity of OF in CRCS ($p<0.001$). Only 7% of men and 27% of women CRCS had OP screening.

Conclusion: Despite a low rate of OP screening, the gender disparity of OF in CRCS is more pronounced than the general population. These findings provide an impetus for studying OP and OF in CRCS.

Mini-abstract:

To explore the rates of osteoporosis (diagnosis & screening), and fractures in colorectal cancer survivors (CRCS), records of clinical trial enrollees was linked to Medicare. Female/male risk of fracture in CRCS is 74% higher than general population. Less than 30% of male and female CRCS receive osteoporosis screening. Osteoporosis is a significant morbidity in CRCS.

Keywords

Osteoporosis; Colorectal Cancer; Survivorship; Medicare Claims; gender disparity

BACKGROUND

Over the past two decades, the number of colorectal cancer survivors and duration of survivorship has risen dramatically. More than 1.5 million colorectal cancer survivors are alive in the United States; the majority will live as survivors with an unaltered life-expectancy.¹ Although surveillance strategies for cancer recurrence are a focus of the early phase of cancer survivorship, there is a limited understanding of long term complications of cancer and cancer related therapies in this population.²

Osteoporosis and osteoporotic fractures are a known complication of hormonal treatments in patients with breast and prostate cancer. For example, the prevalence of osteoporosis is 27% higher and the risk of fractures is 21% higher in breast cancer patients who use aromatase inhibitors (AI) than in the general population.³ In men with prostate cancer on Androgen Deprivation Therapy (ADT), the life time risk of fracture is 20%.⁴ In order to reduce osteoporosis and osteoporotic fractures in these patients, professional societies have developed specific guidelines for screening and treatment of bone health.^{5–8}

Currently, data regarding the prevalence of osteoporosis and osteoporotic fractures following a diagnosis of colorectal cancer is limited, however there are reasons to believe that bone health may be affected in colorectal cancer survivors. Calcium and vitamin D are linked to both colorectal cancer incidence and the development of osteoporosis. Low intake and blood levels of calcium and vitamin D are linked to higher risk of colorectal cancers and increased risk of osteoporosis.^{9–12} Low calcium and vitamin D also can impact the overall survival of colorectal cancer patients.^{13,14} In addition, the majority of colorectal cancer survivors are older than 60 years of age and thus at risk for many age related complications including osteoporosis.²

We explored rates of osteoporosis and osteoporotic fractures using a novel linkage between colorectal cancer patients enrolled on SWOG clinical trials and their Medicare billing claims. This linkage allowed examination of a cohort of cancer patients who were treated

and followed uniformly under protocol guidelines, combining the advantages of prospective staging and treatment data from trial records with long-term assessment of sequelae using Medicare claims.

METHODS

To examine patterns of osteoporosis and osteoporotic fractures in colorectal cancer survivors, we pooled data from SWOG randomized phase III treatment trials S9304, S9415, and S9420 (Table 1).^{15–17} All 3 trials were designed to assess the significance of 5-FU delivery method and modulation on the survival of patients with colorectal cancer, and taken together they showed how the use of infusional 5-FU resulted in lower toxicity than bolus 5-FU with no statistically detectable impact on survival.^{15–17} Both S9304 and S9415 were conducted in patients with resectable colon or rectal cancer, while patients in S9420 had metastatic colorectal cancer. All three trials included 5-FU as part of their treatment.

SWOG subjects were linked to Medicare claims data according to social security number, sex, and date of birth. To enable a minimally sufficient amount of coverage time on Medicare to identify osteoporosis or osteoporotic fractures, only subjects with 12 months of continuous Medicare Parts A&B coverage at any time after registration to the SWOG trial were included. Subjects must simultaneously not have had HMO coverage for at least 12 months, since Medicare claims are not available for individuals in an HMO. Because the required 12 months of Medicare coverage could have happened at any time after registration, patients may not have been 65 years old at randomization, but could have aged into the Medicare claims cohort.

Osteoporosis was identified using ICD9 codes 733.00–733.03, 733.09, 733.90, 733.99. Osteoporosis related fractures were identified using ICD9 codes of 773.10–773.19, 733.81, 733.82, 733.93, 733.98, and 800.00–829.00. These codes are for pathological (i.e., non-traumatic) fractures and are the codes most likely used to identify fractures related to osteoporosis. A systematic review of Medicare claims data by Curtis et. al supports that these codes should be included in the epidemiological evaluation of osteoporosis.¹⁸ We also used Healthcare Common Procedure Coding System (HCPCS) codes for capturing all fractures related to osteoporosis (Supplemental Table 1). Osteoporosis screening was identified using procedure codes specific to bone densitometry as well as bone scan given that bone metastasis and thus bone scan for evaluation of bone metastasis is rare in a colorectal cancer population (Supplemental Table 1).¹⁹ Osteoporosis and osteoporosis related fractures were identified using any hospital claim, or 2 physician or outpatient claims at least 30 days apart, using HCPCS and ICD9 codes (Supplemental Table 1). To focus on the development of new cases of osteoporosis or related fractures, patients with evidence of pre-existing osteoporosis or fractures (prior to trial registration) were excluded from each respective analysis.

Two sets of comparisons were conducted. First, we compared patterns of osteoporosis and osteoporotic fractures by sex in patients with colorectal cancer. Second, we compared the difference in osteoporotic fractures by sex in colorectal cancer patients (using data from the SWOG treatment trials) to the difference in osteoporotic fractures by sex in the general U.S.

population (using data from the U.S. general population). This comparison was conducted to evaluate whether potential sex disparities in osteoporotic fractures differed between cancer and non-cancer patients. Data from the 1994 National Health Interview Survey (NHIS) and the National Hospital Discharge Survey (NHDS) were used to establish patterns of osteoporotic fractures by sex in the U.S. general population.^{20,21} These two databases only include data on osteoporotic fractures, using a restricted set of ICD9 codes. Therefore comparisons between colorectal cancer patients and the general population were limited to osteoporotic fractures only, rather than both osteoporotic fractures and osteoporosis diagnoses.

Statistical Analysis

Baseline descriptive characteristics of SWOG participants were compared using t-tests for continuous measures and chi-square tests for categorical measures.

Analysis comparing male to female colorectal cancer patients

To incorporate time from beginning of observation until evidence of an event (osteoporosis and osteoporotic fracture), and to account for potential competing risks of death, we estimated the cumulative incidence from trial registration until identification of an event according to Medicare claims. Given that osteoporosis is more common in females, in order to estimate the strength of the association between sex and the different time-to-event outcomes, we used Cox regression.²² Some participants experienced gaps in observation, when Medicare coverage was discontinued temporarily for 3 months or longer (gaps <3 months were ignored to allow for minor administrative switching between plans). Participant time-at-risk in Cox models includes only time under Medicare observation. All hazard ratios and p-values were derived from multivariable models that included adjustment for age at registration (<65 vs ≥65), race (black vs other), and BMI (continuous). A set of sensitivity analyses was performed, with metastatic patients (from study S9420) removed.

Analysis comparing risk of fracture by sex in cancer patients versus the general population

We also assessed whether patterns of osteoporotic fracture by sex differed between cancer patients and individuals in the U.S. population. From both the NHDS and NHIS data, we calculated the ratio of the incidence rate per 1,000 person years for females versus males. We specified the mean of these two sex risk ratios as the null hypothesis. In Cox multivariable regression, we tested whether the hazard ratio for fracture risk in SWOG colorectal cancer patients differed from the null hypothesis based on the U.S. general population.

RESULTS

Baseline characteristics of patients included in this analysis, as well as patients from these SWOG studies that were not included in the analysis, are reported in Table 2. No differences were observed between men and women included in this analysis, with respect to age, race, or ethnicity. Those included in the analysis are significantly older than those not included, but there were no differences with respect to race or ethnicity.

Comparing male to female colorectal patients

Table 3 shows rates of osteoporosis, osteoporosis screening, and osteoporotic fractures for male and female colorectal cancer patients. Of note, a minority of both male and female colorectal cancer patients were screened for osteoporosis. Female colorectal cancer survivors were more likely than male survivors to be diagnosed with osteoporosis (HR=4.76 [3.77–6.01], $p<0.0001$), to be screened for osteoporosis (HR=5.15 [3.74–7.09], $p<0.0001$), and to be diagnosed with osteoporotic fracture using all applicable ICD9 codes (HR=2.64 [2.04–3.42], $p<0.0001$). Results were similar using a restricted set of ICD9 codes, to provide a comparison to the US general population (HR=2.90 [2.14–3.93], $p<0.0001$). These results were similar when patients with metastatic disease were excluded from the analysis; in the non-metastatic population only, female colorectal cancer survivors were more likely than male survivors to be diagnosed with osteoporosis (HR=4.85 [3.83–6.14], $p<0.0001$), to be screened for osteoporosis (HR=5.15 [3.74–7.10], $p<0.0001$), and to be diagnosed with osteoporotic fracture using all applicable ICD9 codes (HR=2.68 [2.06–3.50], $p<0.0001$) (Supplemental Table 2).

Comparing risk of fracture by sex in cancer patients versus the general population

Using NHIS data, the rate of fracture per 1,000 person years was 4.6 for females and 2.8 for males, generating a sex risk ratio of 1.64. Using NHDS data, the rate of fracture per 1,000 person years was 21.3 for females and 12.5 for males, generating a sex risk ratio of 1.70 (i.e. 21.3/12.5), very similar to the ratio derived from the NHDS data (Figure 1). We specified our null hypothesis as the mean of these two sex risk ratios, 1.67. The ratio of the risk difference in colorectal cancer survivors (2.90) to the risk difference in the general U.S. cancer population (1.67) indicates that the fracture risk difference by sex is 74% greater in colorectal cancer survivors than in the general U.S. cancer population (Figure 1). A test of the hazard ratio for fracture risk in colorectal cancer patients (2.90) against the null hypothesis of 1.67 generated a p -value $<.001$, indicating that the observed 74% increase in the difference in risk of fracture by sex was highly statistically significant.

Cumulative Incidence of Osteoporosis

Cumulative incidence of osteoporosis diagnoses by sex is plotted in Figure 2, illustrating the dramatic difference between males and females in this population. The cumulative incidence rates for females versus males were 45% versus 12% at 5 years, 68% vs 22% at 10 years, and 83% versus 32% at 15 years.

Discussion

We found that female colorectal cancer survivors were 4.7 times more likely than male survivors to have claims for osteoporosis and 2.6 times more likely to have claims for osteoporotic fractures. The risk difference for osteoporotic fractures between women and men with colorectal cancer was 74% higher than the risk difference between men and women in general population. It has been estimated that in the general population, about 1/3 of women and 1/5 of men over 50 years will experience osteoporotic fractures.^{23,24} Our findings for male colorectal cancer survivors were consistent with these estimates, but our findings for female colorectal cancer survivors were much greater (83% incidence at 15

years; Figure 2). This suggests that the osteoporosis disparity by sex in colorectal cancer survivors is much greater and likely influenced by additional sex-related factors, for females.

Other groups have reported an increased risk of osteoporosis in colorectal cancer survivors compared to non-cancer patients. In an analysis from the General Practice Research Database in the United Kingdom colorectal cancer survivors were compared to the general non-cancer population for their risk of osteoporosis. The definition of osteoporosis was based on diagnosis claims or bisphosphonate prescription codes.²⁵ The authors found that risk of osteoporosis was 40% higher in the colorectal cancer population compared to the non-cancer population, however, risk of osteoporotic fractures was not reported.

There are several factors that may explain the observed findings. First, calcium plays a significant role in both osteoporosis and colorectal cancer risk and its prevention. Calcium is important for bone health and low calcium intake is linked to osteoporosis.^{26,27}

Concurrently, calcium plays a role in development and progression of colorectal cancer via its interactions with the Wnt pathway.^{28,29} Calcium has been identified as a chemopreventive agent for colorectal cancer.³⁰ Calcium absorption happens in the proximal section of small bowel and thus surgery for colorectal cancer has minimal impact if any on the absorption of calcium. Based on several dietary surveys in US, calcium intake is lower in women compared to men, thus putting women cancer survivors at higher risk of osteoporosis.³¹ Furthermore, the impact of calcium intake on the reduction of colorectal cancer mortality in men and women is different.³² Hence, differences in calcium intake and its interaction with colorectal cancer may play a role in the observed differences in osteoporosis between female and male colorectal survivors in our analysis.

Similarly, vitamin D plays a role in the development and progression of colorectal cancer.³³ Low vitamin D levels have been linked to both bone health and risk of several epithelial cancers – including colorectal cancers – and may link colorectal cancer and osteoporosis.^{34–36} Secondary analysis of specimens of N9741 revealed that women compared to men with metastatic colorectal cancer have significantly lower plasma levels of 25(OH)D, an active metabolite of vitamin D.^{37,38} Therefore, dietary intake as well as metabolism of vitamin D may explain the observed difference in osteoporosis and osteoporotic fractures between men and women colorectal cancer survivors.

Hormonal influences in female colorectal cancer patients may play a role in the increased risk of osteoporosis. In other cancers, ovarian dysfunction and early menopause increases the risk of osteoporosis. While 5-FU is unlikely to cause permanent ovarian failure, it is possible that premenopausal women with rectal cancer who receive radiation are at increased risk of ovarian failure and that the radiation may influence bone strength. Nonetheless, an exploratory comparison of osteoporosis and osteoporosis related fracture in our population shows that osteoporosis diagnosis is higher in S9415 (colon cancer population) than it is in S9304 (rectal cancer population).

Although our study suggests a correlation between colorectal cancer and osteoporosis the cause and effect between the two conditions is not established and it may be that osteoporosis increases the risk of colon cancer. Three retrospective studies suggest that

colon adenomas are higher in subjects with osteoporosis.^{39–41} In the study by Lim et al. women with osteoporosis had 60% higher risk of colon adenomas. Gowda et al. report that environmental factors such as smoking may be a confounder in the link between osteoporosis and colon adenoma. Our study excluded pre-existing cases of osteoporosis; however, it is possible that osteoporosis diagnosis that was not reflected in Medicare claims preceded the colorectal cancer diagnosis for some patients – especially women – complicating the interpretation of overall cause and effect.

Finally, it is possible that due to an increase in healthcare interactions, cancer patients are screened for osteoporosis more frequently than non-cancer patients. We found that female cancer survivors were over 5 times as likely to have a claim for bone mineral density than male cancer survivors. Osteoporotic fractures are usually symptomatic and don't need screening for diagnosis.⁴² Therefore, our observation of higher rates of osteoporotic fractures in female colorectal cancer survivors is unlikely to be affected by the rates of screening.

Linkage between clinical trial data and claims is an opportunity to study the long term consequences of cancer diagnosis and treatment related complications. The strength of our study is patient and treatment homogeneity, novel comparison groups and long-term follow-up from claims data. However, our study also has several limitations. First, this study represented a post hoc analysis; osteoporosis was not prospectively evaluated or followed in the study cohort, requiring instead a linkage to Medicare claims which may be limited due to the nature of claims databases, which are not designed for research purposes. Although we have used the standard methods to properly identify osteoporosis using claims, we cannot verify the accuracy of the osteoporosis or osteoporotic fractures. Furthermore, due to the observational nature of the study we cannot provide mechanistic explanation for higher rates of osteoporosis in female colorectal cancer survivors. Additionally, given that our study population are Medicare beneficiaries and thus older, the significance of these findings in a younger cohort of colorectal cancer survivors is unknown. Finally, our results highlight disparities in osteoporosis and osteoporotic fractures by sex, but do not explicitly show whether these disparities are due to higher absolute incidence of events in females or lower absolute incidence of events in males with colorectal cancer compared to the general U.S. population, or some combination thereof.

Our findings are hypothesis generating, and should be confirmed in prospective studies. If confirmed, future studies exploring the mechanisms of osteoporosis and fracture risk should incorporate major risk factors for these conditions including age, family history, and prior fracture history. In the meantime, our claims data show that a minority of colorectal cancer survivors receive osteoporosis screening. Because osteoporosis and subsequent osteoporotic fractures are associated with high rates of mortality and morbidity, understanding populations at increased risk for osteoporosis can increase screening and treatment to prevent osteoporosis fractures.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: None.

Support: Research reported in this publication was partly supported by the National Cancer Institute of the National Institutes of Health under Award Numbers UG1CA189974 and P30CA014089 and a grant from HOPE Foundation.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin* 2016;66:271–89. [PubMed: 27253694]
2. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. *CA Cancer J Clin* 2015;65:428–55. [PubMed: 26348643]
3. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. *Clin Breast Cancer* 2006;7:127–32. [PubMed: 16800971]
4. Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. *J Urol* 2011;186:482–6. [PubMed: 21679977]
5. Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Ann Oncol* 2016;27:379–90. [PubMed: 26681681]
6. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. *Nat Rev Rheumatol* 2013;9:365–74. [PubMed: 23507900]
7. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009;361:745–55. [PubMed: 19671656]
8. National Comprehensive Cancer Networks (NCCN). Clinical Practice Guidelines in Oncology. 2017.
9. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. *J Clin Oncol* 2011;29:3775–82. [PubMed: 21876081]
10. Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev* 2010;19:130–4. [PubMed: 20056631]
11. Keum N, Lee DH, Greenwood DC, Zhang X, Giovannucci EL. Calcium intake and colorectal adenoma risk: dose-response meta-analysis of prospective observational studies. *Int J Cancer* 2015;136:1680–7. [PubMed: 25156950]
12. Keum N, Aune D, Greenwood DC, Ju W, Giovannucci EL. Calcium intake and colorectal cancer risk: dose-response meta-analysis of prospective observational studies. *Int J Cancer* 2014;135:1940–8. [PubMed: 24623471]
13. Maalmi H, Ordonez-Mena JM, Schotker B, Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. *Eur J Cancer* 2014;50:1510–21. [PubMed: 24582912]
14. Yang B, McCullough ML, Gapstur SM, et al. Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: the Cancer Prevention Study-II Nutrition Cohort. *J Clin Oncol* 2014;32:2335–43. [PubMed: 24958826]
15. Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. *J Clin Oncol* 2006;24:3542–7. [PubMed: 16877719]
16. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous

- infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. *J Clin Oncol* 2005;23:1819–25. [PubMed: 15774775]
17. Leichman CG, Benedetti JK, Zalupski MM, et al. Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. *Clin Colorectal Cancer* 2005;5:119–23. [PubMed: 16098253]
 18. Curtis JR, Taylor AJ, Matthews RS, et al. “Pathologic” fractures: should these be included in epidemiologic studies of osteoporotic fractures? *Osteoporos Int* 2009;20:1969–72. [PubMed: 19184268]
 19. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. *Clin Colorectal Cancer* 2005;5:108–13. [PubMed: 16098251]
 20. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. *J Bone Miner Res* 1999;14:456–63. [PubMed: 10027911]
 21. Health data interactive report: Hospital discharges by first- and any-listed diagnosis. Centers for Disease Control and Prevention US, 1990–2010 at <http://205.207.175.93/HDI/TableViewer/tableView.aspx?ReportId=537>.)
 22. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society* 1972;34:187–220.
 23. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. *Osteoporos Int* 2000;11:669–74. [PubMed: 11095169]
 24. Melton LJ 3rd, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. *J Bone Miner Res* 1998;13:1915–23. [PubMed: 9844110]
 25. Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. *Br J Cancer* 2011;105 Suppl 1:S29–37. [PubMed: 22048030]
 26. Riggs BL, Khosla S, Melton LJ 3rd., A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. *J Bone Miner Res* 1998;13:763–73. [PubMed: 9610739]
 27. Sahni S, Mangano KM, McLean RR, Hannan MT, Kiel DP. Dietary Approaches for Bone Health: Lessons from the Framingham Osteoporosis Study. *Curr Osteoporos Rep* 2015;13:245–55. [PubMed: 26045228]
 28. Chakrabarty S, Wang H, Canaff L, Hendy GN, Appelman H, Varani J. Calcium sensing receptor in human colon carcinoma: interaction with Ca(2+) and 1,25-dihydroxyvitamin D(3). *Cancer Res* 2005;65:493–8. [PubMed: 15695391]
 29. MacLeod RJ, Hayes M, Pacheco I. Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. *Am J Physiol Gastrointest Liver Physiol* 2007;293:G403–11. [PubMed: 17463182]
 30. Bonovas S, Fiorino G, Lytras T, Malesci A, Danese S. Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. *World J Gastroenterol* 2016;22:4594–603. [PubMed: 27182169]
 31. Hoy MK, Goldman JD. Calcium intake of the U.S. population. 2014.
 32. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. *J Natl Cancer Inst* 2002;94:437–46. [PubMed: 11904316]
 33. Meeker S, Seamons A, Maggio-Price L, Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. *World J Gastroenterol* 2016;22:933–48. [PubMed: 26811638]
 34. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. *Int J Cancer* 2011;128:1414–24. [PubMed: 20473927]
 35. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. *BMJ* 2010;340:b5500.
 36. Girgis CM, Clifton-Bligh RJ, Mokbel N, Cheng K, Gunton JE. Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells. *Endocrinology* 2014;155:347–57. [PubMed: 24280059]

37. Ng K, Sargent DJ, Goldberg RM, et al. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. *J Clin Oncol* 2011;29:1599–606. [PubMed: 21422438]
38. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2004;22:23–30. [PubMed: 14665611]
39. Gowda S, Lipka S, Davis-Yadley AH, et al. Low bone mineral density linked to colorectal adenomas: a cross-sectional study of a racially diverse population. *J Gastrointest Oncol* 2015;6:165–71. [PubMed: 25830036]
40. Lim JU, Cha JM, Lee JI, et al. Osteoporosis is associated with the risk of colorectal adenoma in women. *Dis Colon Rectum* 2013;56:169–74. [PubMed: 23303144]
41. Nock NL, Patrick-Melin A, Cook M, Thompson C, Kirwan JP, Li L. Higher bone mineral density is associated with a decreased risk of colorectal adenomas. *Int J Cancer* 2011;129:956–64. [PubMed: 20949624]
42. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. *Ann Intern Med* 1998;128:793–800. [PubMed: 9599190]

Figure 1.
Sex Risk Ratio

Figure 2.
Cumulative incidence of osteoporosis diagnoses by sex

Table 1:**Summary of SWOG Studies Included**

Study ID	Publication Title	Population	N Original Study			N linked to Medicare ¹		N included in this study ²		N with osteoporosis claims	
			Total	Male	Female	Male	Female	Male	Female	Male	Female
S9304	Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.	Rectal cancer patients with post resection stage II or III.	1917	1241	676	489	253	445	226	67	108
S9415	Phase III SWOG 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.	Colon cancer patients with high risk stage II or stage III.	1133	598	535	282	264	245	234	38	118
S9420	Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.	Colorectal cancer patients with metastatic disease.	725	415	310	90	57	49	34	4	5

¹ Social Security Number, sex, and date-of-birth match to Medicare records.

² Social Security Number, sex, and date-of-birth match to Medicare records; 12 months of Medicare coverage and no HMO coverage, anytime after SWOG registration.

Table 2:

Descriptive characteristics of participants linked to Medicare claims

Characteristic	Male (N=739)	Female (N=494)	p-value ¹	Not included in this analysis (N=2543)	p-value ²
<i>Baseline</i>					
Age, median (range)	64 (36–86)	65 (25–86)	0.53	58 (18–89)	<0.0001
Race, N (%)			0.07		0.18
Black	49 (7%)	51 (10%)		200 (7%)	
White	665 (90%)	428 (87%)		115 (5%)	
Other	25 (3%)	15 (3%)		2228 (88%)	
Ethnicity, N (%)			0.56		0.16
Non-Hispanic	712 (96%)	479 (97%)		2432 (96%)	
Hispanic	27 (4%)	15 (3%)		111 (4%)	
<i>Post-Baseline</i>					
Osteoporosis and related fractures, N (%)			<0.0001		
No	630 (85%)	260 (53%)			
Yes	109 (15%)	230 (47%)			
Osteoporosis Screening, N (%)			<0.0001		
No	691 (93%)	363 (73%)			
Yes	48 (7%)	131 (27%)			

¹ p-value compares men to women, using t-tests for continuous measures and chi-square tests for categorical measures.

² p-value compares those included in this analysis to those in the SWOG studies but not included in this analysis, using t-tests for continuous measures and chi-square tests for categorical measures.

Table 3:

Association between sex and eventual osteoporosis diagnosis, screening for osteoporosis, and osteoporotic fractures

	Cox Regression						
	No	Yes	5-Yr CI	10-Yr CI	Total CI	HR (95% CI) ^I	P-value ^I
Outcome: Osteoporosis Diagnosis							
Sex							
Male	630	109	12%	22%	32%	Ref	
Female	260	230	45%	68%	83%	4.76 (3.77–6.01)	<0.0001
Outcome: Osteoporosis Screening							
Sex							
Male	691	48	<1%	3%	17%	Ref	
Female	363	131	2%	14%	63%	5.15 (3.74–7.09)	<0.0001
Outcome: Fractures (all ICD9 codes in Supplemental Table 1)							
Sex							
Male	648	91	10%	17%	27%	Ref	
Female	351	142	24%	39%	57%	2.64 (2.04–3.42)	<0.0001
Outcomes: Fractures (ICD9 codes 800.00–829.00)							
Sex							
Male	673	66	7%	12%	20%	Ref	
Female	381	112	19%	32%	47%	2.90 (2.14–3.93)	<0.0001

^I Odds ratios, hazard ratios, and p-values are adjusted for age at baseline (<65 vs ≥65), race (black vs other), and BMI (continuous).